参考文献/References:
[1] 中华医学会骨质疏松和骨矿盐疾病分会,中华医学会内分泌学分会,中华医学会糖尿病学分会,等.糖尿病患者骨折风险管理中国专家共识[J].中华糖尿病杂志,2019,11(7):445-456.DOI:10.3760/cma.j.issn.1674-5809.2019.07.002.
[2] 余洁,许岭翎,李玉秀.1型糖尿病与骨折风险:从机制到临床[J].中华糖尿病杂志,2020,12(6):429-432.DOI:10.3760/cma.j.cn115791-20190917-00340.
[3] Schwartz AV,Vittinghoff E,Bauer DC,et al.Association of BMD and FRAX score with risk of fracture in older adults with type 2 diabetes[J].JAMA,2011,305(21):2184-2192.DOI:10.1001/jama.2011.715.
[4] De Liefde II,Van der Klift M,De Laet CEDH,et al.Bone mineral density and fracture risk in type-2 diabetes mellitus:the Rotterdam study[J].Osteoporos Int,2005,16(12):1713-1720.DOI:10.1007/s00198-005-1909-1.
[5] Claudia PS,Andre Gustavo DV,Barreto FC.The impact of type 2 diabetes on bone metabolism[J].Diabetol Metab Syndr,2017,9:85.DOI:10.1186/s13098-017-0278-1.
[6] Nicodemus KK,Folsom AR.Type 1 and type 2 diabetes and incident hip fractures in postmenopausal women[J].Diabetes Care,2001,24(7):1192-1197.DOI:10.2337/diacare.24.7.1192.
[7] Dytfeld J,Michalak M.Type 2 diabetes and risk of low-energy fractures in postmenopausal women:meta-analysis of observational studies[J].Aging Clin Exp Res,2017,29(2):301-309.DOI:10.1007/s40520-016-0562-1.
[8] Tebé C,Martinez-Laguna D,Moreno V,et al.Differential mortality and the excess rates of hip fracture associated with type 2 diabetes:accounting for competing risks in fracture prediction matters[J].J Bone Miner Res,2018,33(8):1417-1421.DOI:10.1002/jbmr.3435.
[9] Jiajue R,Qi X,Jiang Y,et al.Incident fracture risk in type 2 diabetic postmenopausal women in mainland China:Peking vertebral fracture study[J].Calcif Tissue Int,2019,105(5):466-475.DOI:10.1007/s00223-019-00598-x.
[10] Ekström W,Al-Ani AN,Sääf M,et al.Health related quality of life,reoperation rate and function in patients with diabetes mellitus and hip fracture--a 2 year follow-up study[J].Injury,2013,44(6):769-775.DOI:10.1016/j.injury.2012.10.003.
[11] Walsh JS,Vilaca T.Obesity,type 2 diabetes and bone in adults[J].Calcif Tissue Int,2017,100(5):528-535.DOI:10.1007/s00223-016-0229-0.
[12] Cortet B,Lucas S,Legroux-Gerot I,et al.Bone disorders associated with diabetes mellitus and its treatments[J].Joint Bone Spine,2019,86(3):315-320.DOI:10.1016/j.jbspin.2018.08.002.
[13] Yeung SSY,Reijnierse EM,Pham VK,et al.Sarcopenia and its association with falls and fractures in older adults:a systematic review and meta-analysis[J].J Cachexia Sarcopenia Muscle,2019,10(3):485-500.DOI:10.1002/jcsm.12411.
[14] Volpato S,Bianchi L,Lauretani F,et al.Role of muscle mass and muscle quality in the association between diabetes and gait speed[J].Diabetes Care,2012,35(8):1672-1679.DOI:10.2337/dc11-2202.
[15] Romero-Díaz C,Duarte-Montero D,Gutiérrez-Romero SA,et al.Diabetes and bone fragility[J].Diabetes Ther,2021,12(1):71-86.DOI:10.1007/s13300-020-00964-1.
[16] Kim Y,Park SO,Kim T,et al.The association of serum 25-hydroxyvitamin D and vertebral fractures in patients with type 2 diabetes[J].Endocr J,2013,60(2):179-184.DOI:10.1507/endocrj.ej12-0269.
[17] Starup-Linde J,Vestergaard P.Biochemical bone turnover markers in diabetes mellitus - a systematic review[J].Bone,2016,82:69-78.DOI:10.1016/j.bone.2015.02.019.
[18] Wang L,Li T,Liu J,et al.Association between glycosylated hemoglobin A1c and bone biochemical markers in type 2 diabetic postmenopausal women:a cross-sectional study[J].BMC Endocr Disord,2019,19(1):31.DOI:10.1186/s12902-019-0357-4.
[19] Lee HS,Hwang JS.Impact of type 2 diabetes mellitus and antidiabetic medications on bone metabolism[J].Curr Diab Rep,2020,20(12):78.DOI:10.1007/s11892-020-01361-5.
[20] Ardawi MS,Akhbar DH,Alshaikh A,et al.Increased serum sclerostin and decreased serum IGF-1 are associated with vertebral fractures among postmenopausal women with type-2 diabetes[J].Bone,2013,56(2):355-362.DOI:10.1016/j.bone.2013.06.029.
[21] Paschou SA,Dede AD,Anagnostis PG,et al.Type 2 diabetes and osteoporosis:a guide to optimal management[J].J Clin Endocrinol Metab,2017,102(10):3621-3634.DOI:10.1210/jc.2017-00042.
[22] Nordklint AK,Almdal TP,Vestergaard P,et al.The effect of metformin versus placebo in combination with insulin analogues on bone mineral density and trabecular bone score in patients with type 2 diabetes mellitus:a randomized placebo-controlled trial[J].Osteoporos Int,2018,29(11):2517-2526.DOI:10.1007/s00198-018-4637-z.
[23] Zinman B,Haffner SM,Herman WH,et al.Effect of rosiglitazone,metformin,and glyburide on bone biomarkers in patients with type 2 diabetes[J].J Clin Endocrinol Metab,2010,95(1):134-142.DOI:10.1210/jc.2009-0572.
[24] Zhang Z,Cao Y,Tao Y,et al.Sulfonylurea and fracture risk in patients with type 2 diabetes mellitus:a meta-analysis[J].Diabetes Res Clin Pract,2020,159:107990.DOI:10.1016/j.diabres.2019.107990.
[25] Loke YK,Singh S,Furberg CD.Long-term use of thiazolidinediones and fractures in type 2 diabetes:a meta-analysis[J].CMAJ,2009,180(1):32-39.DOI:10.1503/cmaj.080486.
[26] Zhu ZN,Jiang YF,Ding T.Risk of fracture with thiazolidinediones:an updated meta-analysis of randomized clinical trials[J].Bone,2014,68:115-123.DOI:10.1016/j.bone.2014.08.010.
[27] Ruppert K,Cauley J,Lian Y,et al.The effect of insulin on bone mineral density among women with type 2 diabetes:a SWAN pharmacoepidemiology study[J].Osteoporos Int,2018,29(2):347-354.DOI:10.1007/s00198-017-4276-9.
[28] Napoli N,Strotmeyer ES,Ensrud KE,et al.Fracture risk in diabetic elderly men:the MrOS study[J].Diabetologia,2014,57(10):2057-2065.DOI:10.1007/s00125-014-3289-6.
[29] Losada E,Soldevila B,Ali MS,et al.Real-world antidiabetic drug use and fracture risk in 12,277 patients with type 2 diabetes mellitus:a nested case-control study[J].Osteoporos Int,2018,29(9):2079-2086.DOI:10.1007/s00198-018-4581-y.
[30] Barchetta I,Cimini FA,Bloise D,et al.Dipeptidyl peptidase-4 inhibitors and bone metabolism:is vitamin D the link?[J].Acta Diabetol,2016,53(5):839-844.DOI:10.1007/s00592-016-0882-9.
[31] Monami M,Dicembrini I,Antenore A,et al.Dipeptidyl peptidase-4 inhibitors and bone fractures:a meta-analysis of randomized clinical trials[J].Diabetes Care,2011,34(11):2474-2476.DOI:10.2337/dc11-1099.
[32] Driessen JH,van den Bergh JP,van Onzenoort HA,et al.Long-term use of dipeptidyl peptidase-4 inhibitors and risk of fracture:a retrospective population-based cohort study[J].Diabetes Obes Metab,2017,19(3):421-428.DOI:10.1111/dom.12843.
[33] Fu J,Zhu J,Hao Y,et al.Dipeptidyl peptidase-4 inhibitors and fracture risk:an updated meta-analysis of randomized clinical trials[J].Sci Rep,2016,6:29104.DOI:10.1038/srep29104.
[34] 白秋芳,冯正平.降糖药与骨代谢相关性研究进展[J].中国骨质疏松杂志,2019,25(3):416-420.DOI:35.CNKI:SUN:ZGZS.0.2019-03-023.
[35] Iepsen EW,Lundgren JR,Hartmann B,et al.GLP-1 receptor agonist treatment increases bone formation and prevents bone loss in weight-reduced obese women[J].J Clin Endocrinol Metab,2015,100(8):2909-2917.DOI:10.1210/jc.2015-1176.
[36] Zhang YS,Weng WY,Xie BC,et al.Glucagon-like peptide-1 receptor agonists and fracture risk:a network meta-analysis of randomized clinical trials[J].Osteoporos Int,2018,29(12):2639-2644.DOI:10.1007/s00198-018-4649-8.
[37] Neal B,Perkovic V,Mahaffey KW,et al.Canagliflozin and cardiovascular and renal events in type 2 diabetes[J].N Engl J Med,2017,377(7):644-657.DOI:10.1056/NEJMoa1611925.
[38] Abrahami D,Douros A,Yin H,et al.Sodium-glucose cotransporter 2 inhibitors and the risk of fractures among patients with type 2 diabetes[J].Diabetes Care,2019,42(9):e150-e152.DOI:10.2337/dc19-0849.
[39] Schmedt N,Andersohn F,Walker J,et al.Sodium-glucose co-transporter-2 inhibitors and the risk of fractures of the upper or lower limbs in patients with type 2 diabetes:a nested case-control study[J].Diabetes Obes Metab,2019,21(1):52-60.DOI:10.1111/dom.13480.
[40] Ruanpeng D,Ungprasert P,Sangtian J,et al.Sodium-glucose cotransporter 2(SGLT2)inhibitors and fracture risk in patients with type 2 diabetes mellitus:a meta-analysis[J].Diabetes Metab Res Rev,2017,33(6):e2903.DOI:10.1002/dmrr.2903.
相似文献/References:
[1]曾静波,王姮.2型糖尿病与自身免疫反应[J].国际内分泌代谢杂志,2007,(04):259.
[2]朱素君,谢锦桃,刘军,等.二甲双胍：2型糖尿病治疗的基础药[J].国际内分泌代谢杂志,2007,(04):280.
[3]刘艳清 易秋艳 邵加庆.肠道菌群与肥胖和糖尿病的关系[J].国际内分泌代谢杂志,2015,(01):31.[doi:DOI：10.3760/cma.j.issn.1673-4157.2015.01.007]
Liu Yanqing,Yi Qiuyan,Shao Jiaqing..Relationship between gut microbiota, obesity and diabetes[J].International Journal of Endocrinology and Metabolism,2015,(03):31.[doi:DOI：10.3760/cma.j.issn.1673-4157.2015.01.007]
[4]姚旻 赵爱源 张宏.肠道菌群与2型糖尿病[J].国际内分泌代谢杂志,2015,(01):35.[doi:DOI：10.3760/cma.j.issn.1673-4157.2015.01.008]
Yao Min*,Zhao Aiyuan,Zhang Hong..Relationship between gut microbiota and type 2 diabetes[J].International Journal of Endocrinology and Metabolism,2015,(03):35.[doi:DOI：10.3760/cma.j.issn.1673-4157.2015.01.008]
[5]赵丽娟,徐宽枫,杨涛,等.SLC30A8和PTPRD基因多态性与南京地区中老年人群2型糖尿病的相关性研究[J].国际内分泌代谢杂志,2015,(03):145.[doi:10.3760/cma.j.issn.1673-4157.2015.03.001]
Zhao Lijuan*,Xu Kuanfeng,Yang Tao,et al.Relationship between SLC30A8 and PTPRD gene polymorphisms and type 2 diabetes in middle aged and elderly people in Nanjing area[J].International Journal of Endocrinology and Metabolism,2015,(03):145.[doi:10.3760/cma.j.issn.1673-4157.2015.03.001]
[6]王洁,何媛,于珮.糖尿病肾病的相关危险因素分析[J].国际内分泌代谢杂志,2015,(03):153.[doi:10.3760/cma.j.issn.1673-4157.2015.03.003]
Wang Jie*,He Yuan,Yu Pei..Risk factors of diabetic nephropathy[J].International Journal of Endocrinology and Metabolism,2015,(03):153.[doi:10.3760/cma.j.issn.1673-4157.2015.03.003]
[7]刘帅,张萍,方毅,等.2型糖尿病合并无症状冠状动脉钙化的相关危险因素分析[J].国际内分泌代谢杂志,2015,(03):158.[doi:10.3760/cma.j.issn.1673-4157.2015.03.004]
Liu Shuai*,Zhang Ping,Fang Yi,et al.Analysis of the risk factors related with asymptomatic coronary calcification for type 2 diabetic patients[J].International Journal of Endocrinology and Metabolism,2015,(03):158.[doi:10.3760/cma.j.issn.1673-4157.2015.03.004]
[8]徐庆海,马颖,李铁马.2型糖尿病患者高甘油三酯血症-腰围表型与甲状腺功能异常的关系[J].国际内分泌代谢杂志,2015,(04):222.[doi:10.3760/cma.j.issn.1673-4157.2015.04.002]
Xu Qinghai,Ma Ying,Li Tiema..Association of hypertriglyceridaemic-waist phenotype with thyroid dysfunction in patients with type 2 diabetes mellitus[J].International Journal of Endocrinology and Metabolism,2015,(03):222.[doi:10.3760/cma.j.issn.1673-4157.2015.04.002]
[9]潘道延,沈洁,朱筱,等.利格列汀对2型糖尿病大鼠代谢性内毒素血症的影响[J].国际内分泌代谢杂志,2015,(04):230.[doi:10.3760/cma.j.issn.1673-4157.2015.04.004]
Pan Daoyan,Shen Jie,Zhu Xiao,et al.Effects of linagliptin on metabolic endotoxemia in type 2 diabetic rats[J].International Journal of Endocrinology and Metabolism,2015,(03):230.[doi:10.3760/cma.j.issn.1673-4157.2015.04.004]
[10]黄桥,白洁,杜洪泉.一种新的脂肪细胞因子——cartonectin[J].国际内分泌代谢杂志,2015,(04):265.[doi:10.3760/cma.j.issn.1673-4157.2015.04.014]
Huang Qiao*,Bai Jie,Du Hongquan..A novel adipokine--cartonectin[J].International Journal of Endocrinology and Metabolism,2015,(03):265.[doi:10.3760/cma.j.issn.1673-4157.2015.04.014]